Statins: have we found the Holy Grail?
In coronary artery disease, cardiovascular risk factors are the main targets for primary and secondary prevention. Statins prevent cardiovascular events in patients at risk. However, despite the proven efficacy and safety of statins, relevant side effects exist and should be considered when treating patients.
University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland. rjeger@uhbs.ch
Raban
R
Jeger
Thomas
T
Dieterle
D002318:Cardiovascular Diseases / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D011322:Primary Prevention / Q000379:methods*; D011379:Prognosis; D012307:Risk Factors; D055502:Secondary Prevention / Q000379:methods*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids